NBN Primary Antibody
|Aliases||ATV; NBS; P95; NBS1; AT-V1; AT-V2|
|Formulation||Purified antibody in PBS with 0.05% sodium azide.|
|Immunogen||Purified recombinant fragment of human NBN (AA: 467-615) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|Species Reactivity||Human, Rat|
|ICC (Immunocytochemistry)||1/200 - 1/1000|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using NBN mAb against human NBN (AA: 467-615) recombinant protein. (Expected MW is 44.3 kDa)
Figure 2: Western blot analysis using NBN mAb against HEK293 (1) and NBN (AA: 467-615)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 3: Western blot analysis using NBN mouse mAb against A549 (1), Jurkat (2) and PC-12 (3) cell lysate.
Figure 4: Immunofluorescence analysis of Hela cells using NBN mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)
Figure 5: Flow cytometric analysis of Hela cells using NBN mouse mAb (green) and negative control (red).
Figure 6: Immunohistochemical analysis of paraffin-embedded cervical cancer tissues using NBN mouse mAb with DAB staining.
Figure 7: Immunohistochemical analysis of paraffin-embedded rectum cancer tissues using NBN mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Mutations in this gene are associated with Nijmegen breakage syndrome, an autosomal recessive chromosomal instability syndrome characterized by microcephaly, growth retardation, immunodeficiency, and cancer predisposition. The encoded protein is a member of the MRE11/RAD50 double-strand break repair complex which consists of 5 proteins. This gene product is thought to be involved in DNA double-strand break repair and DNA damage-induced checkpoint activation.
|References (references)||1. Fam Cancer. 2012 Dec;11(4):595-600. |
2. Mol Carcinog. 2011 Sep;50(9):689-96.